Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis by Mohamad Zaidan et al.
Zaidan et al. Annals of Intensive Care 2012, 2:31
http://www.annalsofintensivecare.com/content/2/1/31REVIEW Open AccessVasculitic emergencies in the intensive care unit:
a special focus on cryoglobulinemic vasculitis
Mohamad Zaidan1, Eric Mariotte1, Lionel Galicier2, Bertrand Arnulf3, Véronique Meignin4, Jérôme Vérine4,
Alfred Mahr5 and Élie Azoulay1,6*Abstract
Vasculitis is characterized by the infiltration of vessel walls by inflammatory leukocytes with reactive damage and
subsequent loss of vessel integrity. The clinical course of systemic vasculitis may be punctuated by acute
life-threatening manifestations that require intensive care unit (ICU) admission. Furthermore, the diagnosis may be
established in the ICU after admission for a severe inaugural symptom, mostly acute respiratory failure. Among the
systemic vasculitides, cryoglobulinemic vasculitis (CV) has been rarely studied in an ICU setting. Severe CV-related
complications may involve the kidneys, lungs, heart, gut, and/or central nervous system. The diagnosis of CV in the
ICU may be delayed or completely unrecognized. A high level of suspicion is critical to obtain a timely and
accurate diagnosis and to initiate appropriate treatment. We describe severe acute manifestations of CV based on
six selected patients admitted to our ICU. That all six patients survived suggests the benefit of prompt ICU
admission of patients with severe CV.
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Introduction
Vasculitis is defined by the presence of inflammatory
leukocytes in vessel walls with reactive damage and subse-
quent loss of vessel integrity, which can lead to bleeding,
tissue ischemia, and necrosis [1,2]. The natural course of
as-yet-undiagnosed and untreated systemic vasculitis may
result in acute and life-threatening manifestations that re-
quire management in an intensive care unit (ICU) [3-8].
Cryoglobulinemic vasculitis (CV) is a small-vessel
systemic vasculitis that results from the deposition of
cryoglobulins on the vessel walls, activating the comple-
ment cascade [9-15]. Cryoglobulinemia is defined by the
presence in the serum of one or more immunoglobulins
(Igs) that undergo reversible precipitation at tempera-
tures below 37°C [9-11,15]. The 1974 Brouet classifica-
tion distinguishes three cryoglobulin types based on the* Correspondence: elie.azoulay@sls.aphp.fr
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(Additional file 1: Table S1) [14].
Clinically, the classical triad of purpura, weakness, and
arthralgia is present in up to 80–90% of patients and may
be associated with a broad spectrum of abnormalities, in-
cluding other skin and joint manifestations, as well as in-
volvement of the kidneys, digestive tract, peripheral
nervous system, and salivary glands (Additional file 1: Table
S2) [9-19]. Of note, serum cryoglobulins may be missed
despite repeated testing and a typical cryoglobulinemic syn-
drome. Immune-complex-mediated, necrotizing, or leuko-
cytoclastic small vessel-vasculitis is the pathological
hallmark [9-11,15].
The clinical course of CV is uneventful in more than 50%
of patients [9-11,15]. Fulminant, life-threatening flares are
rare but must be diagnosed and treated promptly [20-23].
Widespread vasculitis, which is defined as involvement of
the skin and at least two other organs, may develop (Table 1;
Figure 1) [9-11,15,20-23]. In a retrospective study of 209
consecutive patients with CV, 29 patients had potentially
life-threatening CV-related manifestations, of which 59%
were present at onset [20]. These manifestations were asso-
ciated with a higher mortality rate and included renaln Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Acute life-threatening manifestations of
cryoglobulinemic vasculitis [9-14,20-23]
Widespread vasculitis - Multiple organ involvement, including
the skin and at least two other organs
(kidney, gut, lung, CNS)





- Focal and segmental glomerulonephritis
Lung involvement - Subclinical alveolitis
- Interstitial lung fibrosis
- Diffuse alveolar hemorrhage
Heart involvement - Acute heart failure
- Acute coronary syndrome
Digestive tract involvement - Ischemic bowel vasculitis
- Gastrointestinal hemorrhage
- Acute intraabdominal organ injury
(pancreatitis, cholecystitis)
CNS involvement - Stroke
- Encephalopathy with impaired
cognitive function
- Brain hemorrhage
- Spinal cord involvement
Other - Hyperviscosity syndrome
- caused by high levels of cryoglobulins
- combines acute respiratory distress,
visual disturbances and retinal
hemorrhage, encephalopathy with
impaired cognitive function, and AKI
- B-cell lymphoproliferative disorders
and related complications
- Sepsis, bacterial infections,
and related complications
- Liver failure in HCV-related mixed
cryoglobulinemia (acute-on-chronic
hepatitis and cirrhosis)
HCV=hepatitis C virus; AKI = acute kidney injury; CNS = central nervous system.
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tinal vasculitis, pulmonary hemorrhage, and central ner-
vous system involvement [20]. The mortality rate reached
100% for patients with pulmonary hemorrhage or intestinal
ischemia. The diagnosis of CV in the ICU may be delayed
or be completely unrecognized. A high level of suspicion is
critical to obtain a timely and accurate diagnosis and to ini-
tiate appropriate treatment. The scope of this review is to
illustrate the potentially life-threatening nature of CV
through the description of six selected patients admitted to
our ICU. Written informed consent was obtained from the
patient for publication of this report and any accompanying
images. The clinical vignette of five patients is detailed, andone patient is only depicted in Figure 1. That all six
patients survived argues strongly in favor of prompt ICU
admission of patients with severe CV.
Illustrative review
Two patients admitted to the ICU for acute respiratory
failure due to CV-related renal involvement
Case 1 renal involvement An 82-year-old female with
an unremarkable medical history presented with recent
onset of purpura, edema, and paresthesia with burning
sensations in her extremities. Her condition worsened
rapidly with acute respiratory distress and oliguria. At
admission to the ICU, her blood pressure was 195/67
mmHg and she had bilateral crackles by lung ausculta-
tion. Chest computed tomography (CT) showed a bilat-
eral pleural effusion and alveolointerstitial infiltrates
(Figures 2a-b). Echocardiography indicated left ven-
tricular diastolic dysfunction. The cryoglobulin test was
positive for type II mixed cryoglobulinemia with a
monoclonal IgM kappa. The serum C3 level was nor-
mal, but the serum C4 level was low. Serological tests
for hepatitis C and B and human immunodeficiency
virus were negative. A skin biopsy revealed leukocyto-
clastic vasculitis, and a kidney biopsy membranoproli-
ferative glomerulonephritis (Figures 2c-d). The patient
complained from xerostomia, and antinuclear and anti-
SSA antibodies were positive. A minor salivary gland
biopsy displayed a mononuclear cell infiltrate consistent
with Sjögren’s syndrome. The diagnosis was primary
Sjögren’s syndrome-related mixed cryoglobulinemia with
peripheral neuropathy, skin lesions, and glomeruloneph-
ritis. The patient received oral prednisone (1 mg/kg/day)
and four weekly infusions of rituximab (375 mg/kg/m² per
week). She improved and her renal function recovered
ad integrum.
Case 2 renal involvement A 66-year-old female, with a
history of type I CV due to a low-grade B-cell lymphoma 2
years before, was admitted to the ICU for acute respiratory
failure. Her temperature was 36°C, heart rate 132 beats per
minute, blood pressure 220/100 mmHg, and oxygen satur-
ation 80%. The physical examination showed peripheral
edema, purpura over the lower limbs, and bilateral lung
crackles. She was rapidly intubated. Laboratory findings
were as follows: hemoglobin, 8.8 g/dL; leukocyte count,
16,800/mm3; platelet count, 292,000/mm3; serum creatin-
ine, 615 μmol/L; serum urea, 24 mmol/L; proteinuria in the
nephrotic range; and hematuria. She experienced two epi-
sodes of nitroglycerin-responsive chest pain with slight
troponin elevation and ST segment depression (Figure 3).
The test for cryoglobulin was positive for type I cryoglobuli-
nemia (IgG kappa), and the C4 level was low with un-
detectable total complement activity. These findings were
Figure 1 Widespread fulminant cryoglobulinemic vasculitis is defined as involvement of the skin and at least two other organs, such
as illustrated by the following case. A 50-year-old woman presented with fever, bilateral purpuric lesions, dyspnea, and acute kidney injury.
The bronchoalveolar lavage showed severe hemorrhage with predominance of macrophages and neutrophils (a, May-Grünwald stain, x200). The
skin biopsy revealed typical features of leukocytoclastic vasculitis with intraluminal thrombosis and fibrinoid-type necrosis associated with
infiltration by neutrophils of the vessel walls in the dermis (b, hematoxylin-eosin-saffron stain, x200). The kidney biopsy displayed
membranoproliferative glomerulonephritis. The glomeruli showed mesangial expansion by increased mesangial cell number and matrix, and
some intracapillary "protein thrombi" (c, Masson’s trichrome stain, x400). A mild endocapillary hypercellularity and duplication of the glomerular
basement membrane with “double contours” were also observed (d, Jones stain, x400). Immunofluorescence study showed granular IgG-positive
deposits with lambda light-chain isotype restriction localized to the glomerular capillary wall, mesangium, and intracapillary thrombi (e, IgG
Immunofluorescence staining, x400, lambda staining not shown). IgM, IgA, and kappa staining were all negative (data not shown). Lambda
staining was comparable to IgG staining (data not shown), which was consistent with renal involvement of type I cryoglobulinemia (IgG lambda).
Finally, the diagnosis was widespread cryoglobulinemic vasculitis with skin, lung, and kidney involvement secondary to monoclonal gammopathy
of undetermined significance associated with Sjögren’s syndrome.
Zaidan et al. Annals of Intensive Care 2012, 2:31 Page 3 of 11
http://www.annalsofintensivecare.com/content/2/1/31consistent with a CV flare associated with low-grade B-
cell lymphoma responsible for renal, skin lesions, and un-
stable angina. Steroids were initiated with daily plasma
exchanges in addition to symptomatic treatment and
hemodialysis. The patient was given low-dose aspirin and
clopidogrel, combined with rituximab (375 mg/m²/week),
and cyclophosphamide pulses (600 mg/m²/month). The
cryoglobulin fell to undetectable levels. Her condition
improved, but the renal function did not recover.
Renal involvement is the most common, severe, CV-
related visceral manifestation, seen in more than one-
third of cases[9-18]. Of 29 patients with life-threatening
CV, 55% of the life-threatening episodes were due toCV-related glomerulonephritis [20]. The renal symptoms
typically consisted of mild proteinuria, microscopic
hematuria, and hypertension [24-27]. More than 50% of
patients had mild renal failure [24-27]. Nephrotic syn-
drome, nephritic syndrome, and acute kidney injury
(AKI) have been reported in 20%, 14–25%, and 9% of
patients, respectively [24,26]. Fluid overload, oliguria, and
metabolic disorders may require urgent renal replacement
therapy, as illustrated by our second case [20,23]. The
main renal biopsy finding is type 1 membranoproliferative
glomerulonephritis (70–80% of patients) [24-27]. Mesan-
gial proliferative glomerulonephritis and focal and seg-
mental glomerulonephritis also have been described
Figure 2 Case 1. Primary Sjögren’s syndrome-related mixed
cryoglobulinemia with peripheral neuropathy, skin lesions, and
glomerulonephritis. The chest radiograph (a) and computed
tomography scan (b) showed bilateral pleural effusion and alveolar
infiltrates. The kidney biopsy showed membranoproliferative
glomerulonephritis with abundant infiltrating monocytes and
intracapillary "protein thrombi" (c, Masson’s trichrome stain, x400)
and “double contours” (d, Jones’ silver stain, x400).
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ular lesions due to heart failure, sepsis, or hemorrhagic
shock. The main short-term complications are AKI, oli-
guria, fluid overload with acute respiratory distress, and
metabolic disorders. End-stage renal disease requiring
long-term dialysis occurs in less than 15–30% of patients,
and only after a course of 10 years in half of the cases
[24,25]. In a retrospective study of 105 patients with CV-
related nephropathy and a mean disease duration of 11
years, factors predicting end-stage renal failure were age
>50 years, splenomegaly, cryocrit >10%, low C3 level, re-
current purpura, initial serum creatinine >136 μmol/L,
and HIV coinfection [24]. Male gender may be correlated
with a higher risk for requiring dialysis [26]. In a series of
146 patients with cryoglobulinemic glomerulonephritis,
age, serum creatinine, and proteinuria at the time of kid-
ney biopsy correlated independently with end-stage renal
failure [26]. CV nephropathy may affect survival severely
[9-11,15,19,24-26]. Retrospective studies have pointed to
renal involvement as a marker of poor prognosis
[9-11,15,19,24-26]. Interestingly, Terrier et al. have shown
recently that a glomerular filtration rate <60 ml/min/1.73
m² at presentation, but not hematuria and proteinuria
>1 g/day, was significantly associated with a poor progno-
sis in multivariate analysis [28]. Of 105 patients with es-
sential mixed cryoglobulinemia and renal involvement,
49% were alive 10 years after the renal biopsy—the main
cause of death was cardiovascular disease—whereas 10-
year survival after CV nephropathy onset was approxi-
mately 80% in a more recent study [24,26]. Cardiovascular
disease, infections, liver failure, non-Hodgkin’s lymphoma,
and other malignancies were the main causes of death
[19,24-26].
Two patients admitted to the ICU for acute respiratory
failure due to CV-related pulmonary or cardiac disease
Case 3 pulmonary disease A 47-year-old male was re-
ferred to our hospital for exertional dyspnea and diffuse
vascular purpura. At admission, his temperature was
36.7°C, his heart rate was 64 beats per minute, his blood
pressure was 174/78 mmHg, and his oxygen satu-
ration was 89%. Laboratory findings were as follows:
hemoglobin, 7.8 g/dL; leukocyte count 3,600/mm3; plate-
let count, 179,000/mm3; serum creatinine, 278 μmol/L;
Figure 3 Case 2. The electrocardiogram was normal at admission (a) and showed minor nonspecific changes (ST segment depression) during an
episode of chest pain at rest (b).
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The ratio of urinary protein to creatinine in random sam-
ples was 1,700 mg/mmol. Serological testing for HCV was
positive. The serum C3 level was normal and the C4 level
was 8 mg/dl (normal, 16–40). Rheumatoid factor was
positive and serum type II cryoglobulinemia was found.
The renal biopsy showed membranoproliferative glomer-
ulonephritis. The patient received two weekly infusions of
rituximab (375 mg/m²/week). Acute respiratory distress
suddenly developed. At admission to the ICU, lung aus-
cultation found bilateral crackles. The peripheral edema
and skin lesions had worsened. Chest radiography and CT
showed bilateral ground-glass opacities and alveolar infil-
trates (Figure 4a-b). The bronchoalveolar lavage fluid con-
tained 59104 cells/mL with 84% macrophages of which
90% were hemosiderin-laden alveolar macrophages
(Figure 4c). Cultures were negative. The diagnosis was
CV-related pulmonary-renal syndrome with diffuse alveo-
lar hemorrhage and membranoproliferative glomerulo-
nephritis. He received three intravenous steroid pulses
(1,000 mg/day) followed by oral prednisone (50 mg/day)
in addition to intravenous cyclophosphamide pulses (600
mg/m²/month). A prompt improvement was noted with
resolution of the purpura and partial recovery of renal
function. Pegylated interferon alfa-2a and ribavirin therapydecreased the HCV load to undetectable levels. The cyclo-
phosphamide was discontinued and the prednisone
tapered.
Lung involvement in CV is mainly characterized by
subclinical alveolitis, which occasionally leads to intersti-
tial lung fibrosis [9,29]. Although only scarce data are
available in the literature, patent pulmonary involvement
has been associated with poor survival in patients with
CV [28]. In the series by Ramos-Casals et al., the mortal-
ity rate reached 100% for patients with pulmonary
hemorrhage [20]. Acute severe pulmonary manifesta-
tions in patients with CV include (1) pulmonary edema,
due to fluid overload caused by kidney and heart failure,
(2) bronchopulmonary and systemic infections, (3) dif-
fuse alveolar hemorrhage, and (4) hyperviscosity-related
pulmonary lesions. Infections, although not specific of
CV, may be precipitated by immunodeficiency related to
the underlying disorder (most notably hematological ma-
lignancies) and drugs used to treat CV (steroids and im-
munosuppressive agents) [9-11,15]. Retrospective studies
indicate that infections are among the leading causes of
death in patients with CV, after cardiovascular events
[19,24-26]. Acute respiratory distress is usually related to
renal and/or heart failure with fluid overload and pul-
monary edema, rather than to specific lung lesions,
Figure 4 Case 3. The chest radiograph (a) showed diffuse
nonspecific alveolar infiltrates. Chest computed tomography (b)
revealed areas of ground-glass attenuation interspersed with normal
areas, as well as a bilateral pleural effusion. The bronchioloalveolar
lavage showed many blue hemosiderin-laden macrophages
consistent with diffuse alveolar hemorrhage (c, Perls’ stain, x400).
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related pulmonary lesions [9,12,13,15,20,23,30-33]. Dif-
fuse alveolar hemorrhage was the most common reasonfor ICU admission of patients with small-vessel vasculitis
in the retrospective series of Khan et al., although none
of the 28 patients displayed CV [5]. Patients with diffuse
alveolar hemorrhage generally present with acute
hypoxemic respiratory failure or hemoptysis and anemia
[5,30-34]. Chest radiography and CT show diffuse pul-
monary infiltrates, suggesting ongoing alveolitis [5,30-
34]. When performed, bronchoscopy usually reveals
blood in the bronchoalveolar lavage fluid. The patho-
logical examination may reveal intraalveolar red blood
cells, fibrin, and eventually hemosiderin-laden macro-
phages, which may take up to 48 or 72 h to accumulate
[30,34]. Diffuse alveolar hemorrhage is associated with a
wide spectrum of disorders, including systemic vasculitis
and connective tissue disease [34]. Diffuse alveolar
hemorrhage occurs in less than 5% of patients with
mixed cryoglobulinemia, irrespective of HCV status, and
is generally associated with CV-related glomeruloneph-
ritis [30-33]. Therefore, CV should be on the list of dif-
ferential diagnoses of pulmonary-renal syndrome
[30,34]. Our case contrasts with other reported cases,
because diffuse alveolar hemorrhage is usually associated
with a poor outcome [30]. It is worth noting that the
lung manifestations occurred shortly after the adminis-
tration of rituximab, a drug whose reported adverse
events include interstitial pneumonitis [35-37]. Interest-
ingly, in patients with HCV-related CV, rituximab may
form a complex with IgM kappa mixed cryoglobulin,
thereby inducing an acute systemic flare of CV [38].
Case 4 cardiac disease A 40-year-old female with
chronic HCV infection was admitted to the ICU for
acute bronchospastic respiratory distress. The
temperature was 39.5°C, the heart rate was 170 beats per
minute, the blood pressure was 200/120 mmHg, and the
respiratory rate was 45 breaths per minute. The troponin
level was slightly increased (0.13 μg/L, N< 0.02 μg/L),
and the electrocardiogram showed T-wave inversion
with normal ST segments. Endotracheal ventilation was
started. Community-acquired pneumonia was suspected
and empirical broad-spectrum antibiotic therapy was
initiated. The patient also received bronchodilators and
oral prednisone (1 mg/kg/day for 5 days). She improved
and was extubated. However, she experienced an episode
of abdominal pain and acute anemia (7.5 g/dL). Upper
gastrointestinal endoscopy showed a cardial ulcer with
no active bleeding. Skin ulcers developed over the legs,
as well as nephrotic syndrome with peripheral edema
and microscopic hematuria but no renal failure.
The diagnosis was HCV-related type II cryoglobuline-
mia involving the skin, joints, and kidneys, and probably
the gut. Steroid therapy was resumed. Acute respiratory
distress developed rapidly. The electrocardiogram
showed T-wave inversion with normal ST segments.
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purpura was noted after the administration of cold
serum to measure cardiac output during Swan-Ganz
catheter insertion. Echocardiography showed left ven-
tricular diastolic dysfunction. The bronchoalveolar
lavage fluid contained 26104 cells/mL with 3.5% neutro-
phils and no hemosiderin-laden alveolar macrophages.
Cultures were negative. The creatinine serum level
increased to 127 μmol/l. Urinalysis showed hematuria
and proteinuria in the nephrotic range. The diagnosis
was respiratory failure due to CV-related heart failure
precipitated by hypertensive crisis and renal involve-
ment. Plasma exchanges were initiated in addition to
symptomatic treatment. Replacement liquids were
warmed before administration. Four weekly rituximab
infusions (375 mg/m²/week) were administered. Riba-
virin was added to pegylated interferon alfa-2a to control
chronic HCV infection. The skin lesions resolved and
the renal function recovered. Coronary angiography
performed a few weeks later showed normal coronary
arteries, suggesting involvement of the coronary
microcirculation, which was consistent with CV-related
heart involvement.
CV-related cardiac disease is a rare but life-threatening
manifestation of CV [9,16,23,39-41]. Systemic disease with
respiratory distress and renal involvement is usually
present in patients with CV-related cardiac disease. Acute
cardiac involvement should be distinguished from long-
term cardiovascular complications, which are among
the leading causes of death in patients with CV
[9,16,19,23,24,26]. Moreover, the previous cardiovascular
status should be considered [40]. CV-related cardiac dis-
ease usually occurs concomitantly with other severe organ
manifestations [39,41]. Heart dysfunction with pulmonary
edema is the main presentation. As reported in our
patients, echocardiography may reveal diastolic and sys-
tolic dysfunction with low cardiac output and segmental
dyskinesia or akinesia. Precipitating factors include: AKI;
hypertensive crisis, which is usually severe and control-
lable only by using multiple antihypertensive medications;
and coronary heart disease [9,23]. Coronary heart disease
is difficult to assess in patients with CV, because typical
chest pain is not always present. The manifestations may
consist only in mild troponin elevation or subtle changes
in T waves or ST segments. CV-related coronary heart dis-
ease usually involves the coronary microcirculation, spar-
ing the major arteries, which are usually normal by
angiography [39]. The etiologic and symptomatic treat-
ment includes antiplatelet agents, anticoagulation, and
beta blockers, in addition to steroids and plasma
exchanges. Cardiac biomarkers and the electrocardiogram
should be monitored closely until the symptoms resolve
and the laboratory data return to normal. After treatment,
the imaging studies, particularly the echocardiogram,should be repeated to assess heart function recovery, as
illustrated by our case 4 [41].
Patient admitted to the ICU with severe gastrointestinal
involvement
Case 5 gastrointestinal involvement A 43-year-old
female with a history of Sjögren’s syndrome-related type
II cryoglobulinemia was hospitalized for recent onset of
ulcers on her legs, acute abdominal pain, and peripheral
edema. Urinalysis showed nephrotic-range proteinuria
and hematuria, and the renal biopsy disclosed membra-
noproliferative glomerulonephritis. By abdominal CT,
she had mild thickening of the left colonic wall consist-
ent with ischemic colitis. Empirical antibiotics and three
daily intravenous methylprednisolone pulses (1,000 mg/
day) followed by prednisone (1 mg/kg/day) were admi-
nistered. Her condition improved, and the steroids were
tapered. Two weeks later, she experienced recurrent se-
vere abdominal pain with high-grade fever. She was
rapidly transferred to the ICU. Early colonoscopy
showed numerous lesions of different ages, some of
which were deep ulcerations without perforation, con-
sistent with ischemic colitis. Empirical broad-spectrum
antibiotics were initiated. Repeated physical examination
demonstrated mild tenderness and peritoneal irritation
over the left side of the lower abdomen. Emergency
laparotomy revealed stercoral perforation of the colon.
Colectomy followed by colostomy was performed. The
pathological findings confirmed the diagnosis of CV-
related ischemic colitis (Figure 5). In the meantime, mild
dyspnea and a bilateral pleural effusion developed. The
electrocardiogram and troponin levels were unchanged.
Echocardiography indicated severe left ventricular dys-
function with septal akinesia. The diagnosis was a CV
flare involving the skin, gut, kidneys, and heart. Intra-
venous cyclophosphamide pulse therapy (500 mg/m²)
was added to the steroids and symptomatic treatment. A
prompt improvement was noted, with resolution of the
dyspnea and pleural effusion. She was discharged. Sec-
ondary bowel anastomosis was performed a few months
later. Her cardiac abnormalities improved. Monthly
intravenous cyclophosphamide pulses (500 mg/m²/
month) were given for 9 months. The steroids were
tapered to 5 mg/day and hydroxychloroquine was added
to the long-term treatment regimen.
Gastrointestinal involvement is rare in patients with
CV (5%) [9,13,15,16,19-21,42-44]. CV may cause ische-
mic bowel disease, gastrointestinal hemorrhage, periton-
itis, and acute lesions of any of the intraabdominal
organs, including the pancreas and gallbladder
[13,20,21,42-44]. In a case-control study of 163 patients
who had HCV-related CV and polyarteritis nodosa-like
vasculitis, gastrointestinal involvement was observed in
Figure 5 Case 4. Contrast-enhanced computed tomography of the
abdomen (a) showed circumferential wall thickening and
heterogeneous enhancement with layers of low attenuation
consistent with colonic edema. Pathological analysis of colectomy
specimen revealed severe necrosis with complete loss of crypts,
hemorrhage and infiltration of the colon by inflammatory cells (b,
hematoxylin-eosin-saffron stain, x200). Small-vessel vasculitis was
observed with fibrinoid necrosis and vessel wall infiltration by
neutrophils (c, hematoxylin and eosin stain, x400).
Zaidan et al. Annals of Intensive Care 2012, 2:31 Page 8 of 11
http://www.annalsofintensivecare.com/content/2/1/31only four patients with histologicallydocumented CV
[44]. In patients with HCV-related systemic vasculitis,
gastrointestinal lesions may be related to CV or polyar-
teritis nodosa-like vasculitis, although the test for serumcryoglobulin is usually positive [44]. Pathological studies
may assist in the differential diagnosis [44]. Severe mani-
festations include acute surgical complications (periton-
itis/perforation, mesenteric infarction, and cholecystitis),
intestinal bleeding, and pancreatitis [20,44]. Gastrointes-
tinal lesions are associated with an increased likelihood
of renal and cardiac involvement [44]. Early diagnosis
and management can lead to a favorable outcome, as in
our case [44].
Other potentially life-threatening manifestations of
cryoglobulinemic vasculitis
Neurological manifestations consist chiefly of peripheral
neuropathy, particularly sensory and mixed polyneuritis
[9-15,45]. CV-related central nervous system manifesta-
tions, including stroke, brain hemorrhage, and encephal-
opathy, with impaired cognitive function are exceedingly
rare [13,16,20,45-50]. Spinal cord involvement has been
described [13]. The underlying mechanisms remain un-
clear but may involve either multiple, small, brain
infarcts or small-vessel vasculitis [45].
Hyperviscosity syndrome due to high cryoglobulin
levels is another rare but life-threatening complication
of CV and is seen mainly in patients with lymphoproli-
ferative disorders, chiefly Waldenström’s macroglobuli-
nemia [9,10,12,51]. The clinical presentation may
combine acute respiratory distress, visual disturbances
and retinal hemorrhage, encephalopathy with impaired
cognitive function, and AKI [10,51]. Hydration, steroids,
and other immunosuppressive agents, as well as plasma
exchange, should be initiated rapidly in patients with
hyperviscosity syndrome [9-11,15,52,53].
Liver failure is a major concern in patients with HCV-
related CV [9-13,15,19,20,23,24]. Acute-on-chronic liver
failure or cirrhosis is the result of chronic active HCV
infection rather than specific CV-related hepatic lesions
[9,10,27].
Severe infections with septic shock may occur during
the course of CV, particularly in patients receiving ster-
oids and immunosuppressive agents or undergoing renal
replacement therapy or plasma exchanges [19,24,26].
Management of severe acute CV-related manifestations
In clinical practice, particularly in the ICU, the manage-
ment of life-threatening vasculitis is challenging [3,4,9].
A timely and accurate diagnosis is mandatory for the ap-
propriate treatment to be implemented. The treatment
has three targets: the symptoms, the cause, and the
pathogenic mechanism [3,4,9-11,15,20,23,52]. In critic-
ally ill patients, the first-line treatment focuses on organ
support and prevention of long-term organ dysfunction.
Treatments targeting the pathogenic mechanisms consist
of steroids, immunosuppressive agents, and sometimes
plasma exchange [4]. These treatments should be tailored
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function in each individual patient [4,9-11,15,52,54]. Al-
though no data from controlled, randomized, clinical trials
are available, guidelines have been developed [52]. In critic-
ally ill patients with CV, the first-line treatment aims at re-
versing the pathogenic mechanisms and consists of high-
dose steroids (intravenous methylprednisolone pulses of
500–1000 mg/day for 3 days, followed by oral prednisone 1
mg/kg/day) and some of the time plasma exchanges
(3 liters of plasma per exchange, three times a week for 2–3
weeks) [9-11,15,52,53]. Immunosuppressive drugs—cyclo-
phosphamide (2 mg/kg/day orally or 600 mg/m²/month
intravenously for 2–4 months) or rituximab (375 mg/m²/
week for 4 weeks)—should be considered promptly
[9-11,15,52,53]. Early plasma exchanges are mandatory in
patients with hyperviscosity syndrome [9-11,15,52,53].
Plasma exchanges aim at reducing the levels of circulating
immune complexes, especially those containing cryoglobu-
lins, whereas steroids and immunosuppressive agents help
to reduce the production of cryoglobulins and to limit
the inflammatory process in the blood vessel wall
[9-11,15,52,53]. Paradoxical precipitation of cryoglobulins
has been reported after infusion of cold plasma, suggesting
that replacement fluids for plasma exchange in CV should
be warmed before infusion [55].
Identification of the underlying cause is mandatory and
an etiology-based treatment is the mainstay of the long-
term management [9-11,15,52,53]. Interestingly, in the
study by Ramos-Casals et al. that reported a high mortality
rate in patients with life-threatening CV, most patients
were HCV-positive and received immunosuppressant
agents without antiviral therapy, which could have been
deleterious [20]. In case of HCV-related CV, the eradica-
tion of HCV infection is crucial [9-11,15,52,53]. Antiviral
therapy for 12 months consisting of standard or pegylated
interferon-alpha combined with ribavirin is the reference
standard and should be given whenever possible
[9-11,15,52,53]. Of note, ribavirin is best avoided if the
glomerular filtration rate is <50 mL/min/1.73 m² to avoid
hemolytic anemia [52]. Moreover, it has been reported that
interferon initiation during acute CV onset may result in
paradoxical exacerbation of CV-related manifestations [56].
Patients should be monitored closely for immune-mediated
side effects of interferon therapy or ribavirin [52].
In a recent large study, Terrier et al. has showed that
rituximab plus steroids had the greater therapeutic effi-
cacy compared with steroids alone and alkalinating
agents plus steroids to achieve complete clinical, renal,
and immunological remission and a prednisone dosage
<10 mg/day at 6 months [57]. However, this regimen
was associated with severe infections, particularly when
high doses of corticosteroids were used, whereas death
rates did not differ between the therapeutic regimens
[57]. Of note, only patients with underlying low-grade B-cell lymphoma or with refractory disease after rituximab
and cyclosphamide as single agents should be adminis-
tered combined rituximab plus cyclophosphamide ther-
apy. Finally, patients with glomerulonephritis should
receive angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers and antihypertensive
drugs to achieve the blood pressure and proteinuria tar-
gets established for patients with chronic kidney disease.
This approach is crucial to minimize the long-term car-
diovascular complications, which are the leading cause of
death in patients with CV-related nephropathy [26,52].
Conclusions
The natural course of systemic vasculitis may be punctu-
ated by acute and life-threatening manifestations that re-
quire management in an intensive care unit (ICU). The
diagnosis may be delayed or completely unrecognized.
The six cases reported here illustrate the challenges
raised by the diagnosis and management of a specific
type of small-vessels vasculitis, i.e.,cryoglobulinemic vas-
culitis (CV), particularly in the ICU. CV usually runs a
slow course, but acute flares with life-threatening mani-
festations may occur. A high level of suspicion is essen-
tial, and all CV patients should be monitored closely to
ensure a timely and accurate diagnosis and to initiate ap-
propriate treatment. Acute respiratory distress and AKI
were the main reasons for ICU admission in our
patients. Other serious manifestations that should be
considered are involvement of the lungs, heart, central
nervous system, and gut. Patients usually present with
multiorgan failure, and the possibility of widespread vas-
culitis should be considered. Identification of the under-
lying cause is crucial, because adding etiology-based
treatment to the life-supporting interventions and im-
munosuppressive therapy is likely to improve the
outcome.
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